|
February 3, 2012
|
| 12:26 EDT |  | EW |
|
| 12:00 EDT |  | EW |
| theflyonthewall.com: | Edwards Lifesciences falls 11.2% | | Edwards Lifesciences is down 11.2%, or $9.05, to $71.62 :theflyonthewall.com |
|
| 11:26 EDT |  | EW |
| theflyonthewall.com: | Edwards sinks after Q1 guidance misses expectations | | Edwards Lifesciences (EW) reported Q4 adjusted EPS of 62c, compared with analysts' consensus estimate of 59c. The adjusted EPS excludes several items, including a pre-tax $17.6M special charge related to southern European receivables risk, a global realignment charge and a legal settlement. The company's revenue came in lower than expected. Moreover, Edwards provided Q1 adjusted EPS guidance of 47c-49c, versus the consensus estimate of 55c, and the company expects its Q1 revenue to also come in lower than expected. Edwards' Q1 EPS guidance excludes several special items, the company said. Edwards reiterated its 2012 EPS guidance of $2.70-$2.80, excluding special items, as well as its 2012 transcatheter heart valve sales guidance of $560M-$630M. Edwards' guidance assumes a mid-year 2012 approval of Cohort A of the Partner Trial of its Sapien heart valve, the company said. "We have just begun offering our life saving Sapien technology to many inoperable U.S. patients suffering from severe aortic stenosis and also anticipate making it available for patients whose conditions place them at high risk for surgery," said Edwards CEO Michael Mussallem. In a note to investors, Jefferies recommended buying the stock on weakness today, as the firm believes that the company's outlook is largely unchanged following the results. Jefferies maintains a positive bias and Buy rating on the stock. In late morning trading, Edward dropped $9.36, or 11.60%, to $71.31. :theflyonthewall.com |
|
| 10:31 EDT |  | EW |
| theflyonthewall.com: | On The Fly: Analyst Downgrade Summary | | Today's noteworthy downgrades include: Research in Motion (RIMM) downgraded to Underperform from Hold at Jefferies...Cablevision (CVC) downgraded to Underweight from Neutral at JP Morgan...Edwards Lifesciences (EW) downgraded to Market Perform from Outperform at Wells Fargo...Rofin-Sinar (RSTI) downgraded to Neutral from Overweight at Piper Jaffray...Kforce (KFRC) downgraded to Hold from Buy at Deutsche Bank...Airgas (ARG) downgraded to Neutral from Buy at Goldman...Vertex Pharmaceuticals (VRTX) downgraded to Neutral from Buy at Goldman...Aetna (AET) downgraded to Buy from Conviction Buy at Goldman...Amerigroup (AGP) downgraded to Neutral from Buy at Goldman...ONEOK (OKE) downgraded to Neutral from Buy at Citigroup...Acme Packet (APKT) downgraded to Underperform from Neutral at Mizuho...RadioShack (RSH) downgraded to Equal Weight from Overweight at Morgan Stanley...Brocade (BRCD) downgraded to Market Perform from Outperform at JMP Securities...Merck (MRK) downgraded to Neutral from Buy at Davenport...CarMax (KMX) downgraded to Sector Perform from Outperform at RBC Capital...International Paper (IP) downgraded to Sector Perform from Outperform at RBC Capital...Abercrombie & Fitch (ANF) downgraded to Neutral from Outperform at Macquarie...Rowan Companies (RDC) downgraded to Neutral from Outperform at Macquarie. :theflyonthewall.com |
|
| 10:07 EDT | | EW |
| theflyonthewall.com: | Corrected: Gappers reports | | The gapping stocks reports this morning included stocks that traded below $10. All other aspects of the stories remain the same. :theflyonthewall.com |
|
| 10:01 EDT | | EW |
|
| 09:38 EDT |  | EW |
| theflyonthewall.com: | Edwards Lifesciences shares defended at Goldman | | :theflyonthewall.com |
|
| 09:00 EDT | | EW |
|
| 08:14 EDT | | EW |
|
| 07:39 EDT |  | EW |
|
| 07:10 EDT | | EW |
|
| 05:46 EDT | | EW |
| theflyonthewall.com: | Edwards Lifesciences downgraded to Market Perform from Outperform at Wells Fargo |
 Subscribe for More Information :theflyonthewall.com |
|
|
February 2, 2012
|
| 16:09 EDT |  | EW |
| theflyonthewall.com: | Edwards Lifesciences backs FY12 revenue view $1.95B-$2.05B vs. consensus $2.01B |
Subscribe for More Information :theflyonthewall.com |
|
| 16:09 EDT | | EW |
|
| 16:07 EDT | | EW |
|
| 15:12 EDT | | EW |
|
| 14:05 EDT | | EW |
| theflyonthewall.com: | FDA and industry reach agreement in principle on medical device user fees | | The FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorization of a medical device user fee program. The recommendations would authorize the FDA to collect $595M in user fees over five years, plus adjustments for inflation. Details of the agreement, such as the fee structure, are expected to be finalized soon. :theflyonthewall.com |
|
| 10:19 EDT | | EW |
| theflyonthewall.com: | On The Fly: Analyst Downgrade Summary | | Today's noteworthy downgrades include: Autoliv (ALV) downgraded to Sell from Buy at Citigroup...JDSU (JDSU) downgraded to Neutral from Buy at UBS...Vanguard Health (VHS) downgraded to Market Perform from Outperform at Wells Fargo...Steel Dynamics (STLD) downgraded to Neutral from Buy at BofA/Merrill...AK Steel (AKS) downgraded to Underperform from Neutral at BofA/Merrill...Northrop Grumman (NOC) downgraded to Underperform from Neutral at BofA/Merrill...Sykes Enterprises (SYKE) downgraded to Neutral from Outperform at RW Baird...NYSE Euronext (NYX) downgraded to Market Perform from Outperform at BMO Capital...QuinStreet (QNST) downgraded to Hold from Buy at ThinkEquity...Edwards Lifesciences (EW) downgraded to Neutral from Outperform at Credit Suisse...Ann Inc. (ANN) downgraded to Underweight from Neutral at Piper Jaffray...Johnson & Johnson (JNJ) downgraded to Market Perform from Outperform at First Global. :theflyonthewall.com |
|
| 06:23 EDT | | EW |
|
|
January 31, 2012
|
| 08:10 EDT | | EW |
|
|
January 30, 2012
|
| 16:17 EDT | | EW |
|
| 07:21 EDT |  | EW |
|
